IO360°

Call for Papers

Immuno-Oncology 360° reports on the most current data and rapid advancements to help IO stakeholders:

• Be at the forefront of the most relevant research and developments from key leadership who are at the pulse of cancer immunotherapy
• Foster collaboration amongst those working in all aspects of cancer immunotherapy together under one roof
• Partner to expand technology platforms to develop therapeutics at an accelerated rate
• Receive the latest pre-clinical, translational and clinical data from academia and industry
• Create and prioritize strategies targeted toward specific tumor types
• Identify and gain a greater understanding of what assets are available for potential combinations
• Hear from IO clinical trial leaders as they cover trial design, clinical operations, the latest outcomes and lessons learned
• Get key investor and analyst evaluations and insights on the IO landscape, challenges and what’s next
• Learn about biomarker advancements in vaccines, imaging, neoantigen approaches and more
• Obtain coverage on a wide range of emerging technologies